Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, has entered a strategic research collaboration and license option agreement with Sanofi in the area of metabolic disease. According to Exscientia, delivery of new therapies for metabolic disease, such as diabetes, is hampered by a paucity of single targets that are amenable to drug discovery. To address this challenge, it says it will apply its unique platform to identify and validate com...